진행성 비소세포폐암의 이차항암화학요법으로서 Docetaxel 단독요법의 성적
Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
권선중 (침례신학대학교)
정성수 (충남대학교)
김주옥 (충남대학교)
김선영 (충남대학교)
이정은 (충남대학교)
장필순 (충남대학교)
이연선 (충남대학교)
안진영 (충남대학교)
- 다운로드 수
- 조회수
Abstract
Background : The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second-line chemotherapy, for which Docetaxel (Taxotere??) has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum- based chemotherapy. Methods : Thirty one patients with non-small-cell lung cancer, who had failed first-line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either 75 mg/m2 or 100 mg/m2, with routine premedication every three weeks. Results : Fourteen patients (45.2%) had a partial response. The median survival and progression-free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age (< 60 years: 20.1 months vs. ≥ 60 years: 6.6 months, p = 0.0105) and the histological type (adenocarcinoma: 25.6 months vs. others: 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment-related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses.Conclusion : Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small- cell lung cancer who failed first-line platinum-based chemotherapy. (Tuberc Respir Dis 2005; 58: 465-472)
- keywords
- Docetaxel, Non-small cell lung cancer, Second-line chemotherapy
참고문헌
(2001) Cancer burden for the year 2000 : ihe global picture. ,
(1998) Experience with new chemotherapeutic agents in non-small cell lung cancer. ,
(1995) Summary of phase II data of docetaxel an active agent in the first- and second-line treatment of ad,
(2002.http) Kosary CL. SEER Cancer Statistics Reviews, 1973-1999. Bethesda, MD: National Cancer Institute,
(2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy,
(2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy re,
Schiller JH. An update on North American randomized studies in non-small cell lung cancer.,
(2001) Chemotherapy for advanced non-small cell lung cancer,
et al. New aspects in staging of lung cancer. Cancer 1992,
. Chemotherapy in non-small cell lung cancer a meta- analysis using updated data on individual patients from 52 randomized clinical trials. ,
(1981) Reporting results of cancer treatment,
(1997) Clinical practice guidelines for the treatment of unresectable non- small cell lung cancer adopted on May 16 1997 by the American Society of Clinical Oncology.,
(2002) Gandara DR. Non-small cell lung cancer progression after first-line chemotherapy. ,
(1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non- small cell lung cancer,
(2000) Postmus PE. Second-line chemotherapy in relapsing or refractory non-small cell lung cancer a review,
(2003) Retrospective analysis of safety and efficacy of low-dose Docetaxel 60mg/m2 in advanced non-small cell lung cancer patients pre viously treated with platinum-based chemotherapy,
(2004) Biweekly docetaxel as second- line chemotherapy of patients with advanced non- small cell lung cancer a phase II study of the Galician lung cancer group,
- 다운로드 수
- 조회수
- 0KCI 피인용수
- 0WOS 피인용수